Clinical evaluations of oncologic outcomes in patients with non-urothelial bladder cancer

Abstract

Bladder cancer has the highest recurrence rate of any malignancy. Although most patients with bladder cancer can be treated with organ-sparing therapy, most experience either recurrence or progression, creating a great need for accurate and diligent surveillance. More than 90% of the urinary bladder malignancies are represented by urothelial carcinomas.  Trans - uretheral resection of bladder tumor (TURBT) provides the necessary material for histopathological examination as it allows assessment of degree of differentiation, depth of invasion, and other parameters required for diagnosis and prognosis assessment. Hence the present study was planned to evaluate the clinical evaluations of oncologic outcomes in patients with nonurothelial bladder cancer.The present study was planned in the Department of Urology,Hanumant Hospital, Bhavnagar, Gujarat and Kurji Holy Family Hospital, Patna, Bihar, India. The study was performed from the June 2016 to May 2019. The patients diagnosed with bladder cancer and referred to our hospital were enrolled in the present study. All the patients were informed and consents taken. The aim and the objective of the present study were conveyed to them. Approval of the institutional ethical committee was taken prior to conduct of this study. The data generated from the present study concludes that early detection and treatment of new / recurrent cases is required to optimize bladder preservation, reduce patient morbidity and increase quality of life. The incidence of bladder tumors of both urothelial and non-urothelial varieties is significantly lower in patients less than 40 years.